贝伐单抗治疗复发或晚期转移性乳腺癌的临床价值  

Clinical value of Bevacizumab for recurrent or advanced metastatic breast cancer

作　　者：余宗艳[1] 齐宇红[1] 梁军[1] 

机构地区：[1]第四军医大学唐都医院放疗科,陕西西安710038

出　　处：《现代肿瘤医学》2014年第5期1206-1208,共3页Journal of Modern Oncology

摘　　要：分子靶向治疗是当前乳腺癌治疗领域研究的热点,贝伐单抗是第一个获得批准上市的抑制肿瘤血管生成的药,也是继抗Her-2靶向治疗领域之后另一全新领域。抗肿瘤血管靶向治疗领域;但目前关于贝伐单抗用于乳腺癌的有效性及安全性具有争议。本文汇总国内外关于贝伐单抗治疗乳腺癌的最新研究进展,并评价其临床使用价值。Molecular targeted theraPy is the hotsPot in research of breast cancer. Bevacizumab is listed on the first aPProval of inhibiting tumor angiogenesis drug,is the resistance to targeted its eer - 2 after another new field - the treatment of anti - tumor vascular targeted theraPy field. But the clinical value of Bevacizumab for advanced or meta-static breast cancer are hot disPuting. We summarize the latest Progress of bevacizumab treatment for breast cancer at home and abroad,to evaluate the clinical value of Bevacizumab.

关 键 词：乳腺癌 靶向治疗 贝伐单抗 紫杉醇 

分 类 号：R737.9[医药卫生—肿瘤]